ANVS401, an investigational therapy for neurodegenerative diseases being developed by Annovis Bio, improved the speed and coordination of people with Parkinson’s disease in a Phase 2a clinical trial, an interim analysis suggests.
“The results from this interim analysis are very encouraging. This brings us one step closer to evaluating whether our approach may translate into a novel treatment option for patients suffering from a range of neurodegenerative diseases,”
Thanks for sharing!
Link to the press release:
irpages2.eqs.com/websites/a...
Company gives P values for improvements but does not state actual amount of improvement, which suggests that these numbers are unimpressive
Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS TrialLight Therapy Clinical Trial
Aspen FINALLY Moving forward with Stem Cell Trials 
Trials coming from Zhittya 
Supplement Nichi Glucan appears safe and may be worth a PD trial - I would welcome any feedback on the linked documents.
